Alfacalcidol

Bone resorption inhibitor CAS# 41294-56-8

Alfacalcidol

Catalog No. BCC4962----Order now to get a substantial discount!

Product Name & Size Price Stock
Alfacalcidol: 5mg $92 In Stock
Alfacalcidol: 10mg Please Inquire In Stock
Alfacalcidol: 20mg Please Inquire Please Inquire
Alfacalcidol: 50mg Please Inquire Please Inquire
Alfacalcidol: 100mg Please Inquire Please Inquire
Alfacalcidol: 200mg Please Inquire Please Inquire
Alfacalcidol: 500mg Please Inquire Please Inquire
Alfacalcidol: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Alfacalcidol

Number of papers citing our products

Chemical structure

Alfacalcidol

3D structure

Chemical Properties of Alfacalcidol

Cas No. 41294-56-8 SDF Download SDF
PubChem ID 5282181 Appearance Powder
Formula C27H44O2 M.Wt 400.65
Type of Compound N/A Storage Desiccate at -20°C
Synonyms 1-Hydroxycholecalciferol
Solubility DMSO : ≥ 50 mg/mL (124.80 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
SMILES CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
Standard InChIKey OFHCOWSQAMBJIW-AVJTYSNKSA-N
Standard InChI InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Alfacalcidol

DescriptionMetabolite and prodrug of vitamin D3. Improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.

Alfacalcidol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Alfacalcidol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Alfacalcidol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4959 mL 12.4797 mL 24.9594 mL 49.9189 mL 62.3986 mL
5 mM 0.4992 mL 2.4959 mL 4.9919 mL 9.9838 mL 12.4797 mL
10 mM 0.2496 mL 1.248 mL 2.4959 mL 4.9919 mL 6.2399 mL
50 mM 0.0499 mL 0.2496 mL 0.4992 mL 0.9984 mL 1.248 mL
100 mM 0.025 mL 0.1248 mL 0.2496 mL 0.4992 mL 0.624 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Alfacalcidol

Alfacalcidol is an analogue of Vitamin D and a potent inhibitor of bone resorption [1].

Alfacalcidol has been revealed to play a part in bone and mineral homeostasis via binding to the VDR (vitamin D receptor) in calcium-related target organs, such as intestine, bone, kidney and parathyroid gland. In addition, in a high bone-turnover state after OVX, Alfacalcidol has been reported to inhibit osteoclastic bone resorption at pharmacological doses that do not cause hypercalcemia. Apart from these, Alfacalcidol has shown the stimulative effect to the bone formation. Furthermore, Alfacalcidol has been found to enhance bone mass and bone strength at given serum and urinary calcium levels in the OVX model.

References:
[1] Shiraishi A1, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000 Apr;15(4):770-9.

Featured Products
New Products
 

References on Alfacalcidol

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors.[Pubmed:27446535]

Biomed Rep. 2016 Aug;5(2):165-170.

It has been indicated that proton pump inhibitor (PPI) use is associated with a loss of the anti-fracture efficacy of alendronate (AD). However, there are few prospective studies that have investigated the efficacy of AD on lumbar bone mineral density (BMD) in osteoporotic patients who are using PPIs. Thus, the aim of the present study was to investigate the efficacy of Alfacalcidol (AC) and AD on lumbar BMD in osteoporotic patients using PPIs. A prospective, randomized, active control study enrolled such osteoporotic patients (age, >/=50 years). The patients were randomly assigned to receive AC (1 microg/day) or AD (35 mg/week) and were followed up for one year. Patient profiles were maintained, and lumbar BMD, bone-specific alkaline-phosphatase (BAP) and collagen type-I cross-linked N-telopeptide (NTX), upper gastrointestinal endoscopy results, and the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) were evaluated. Percentage changes in lumbar BMD, NTX, BAP, and change in FSSG score from baseline to the end of one year of treatment were investigated. Sixteen patients were eligible for analysis (eight assigned to receive AC, eight assigned to receive AD). The percentage change in lumbar BMD from baseline to the end of treatment was -0.4+/-4.0% for the AC group vs. 6.8+/-6.3% for the AD group (P=0.015). No significant percentage change of BAP and NTX between the two groups was observed. Subsequent to one year of treatment, the FSSG score did not change from the baseline values for either study group, and no new bone fractures or esophagitis were observed in either group of patients. The findings demonstrated that in osteoporotic patients using concomitant PPIs, there was a greater increase in lumbar BMD after one year of treatment with AD compared with AC. However, the number of study subjects was small; thus, further, large prospective studies are required to determine the effect of AD in osteoporotic patients using concomitant PPIs.

Effects of 1alpha-Calcidol (Alfacalcidol) on Microvascular Endothelial Function, Arterial Stiffness, and Blood Pressure in Type II Diabetic Nephropathy Patients.[Pubmed:26749451]

Microcirculation. 2016 Jan;23(1):53-61.

OBJECTIVES: To determine the effects of six months Alfacalcidol on microvascular endothelial function, arterial stiffness, and BP in DN patients. METHODS: Twenty-eight DN patients on Alfacalcidol, 0.25 mug daily for six months were compared to 32 controls on conventional treatment. Measurements of microvascular endothelial function, arterial stiffness [AIx and PWV], hsCRP, and BP were performed; differences between baseline and six months treatment were evaluated. RESULTS: No difference was seen in microvascular endothelial function for both groups after six months. Improvement in CSBP (p = 0.027) with trends of improvement in AIx (p = 0.063), PWV (p = 0.075), and systolic BP (p = 0.088) were seen in the Alfacalcidol group with no changes observed in controls. Subgroup analysis of Alfacalcidol group showed that vitamin D-deficient patients had better response to treatment. hsCRP level remained unchanged in Alfacalcidol group; significant increase was however seen in controls. CONCLUSION: Alfacalcidol did not have an effect on microvascular endothelial function in DN patients. Alfacalcidol significantly improved CSBP with trends of improvement in arterial stiffness and peripheral BP. Alfacalcidol appears to be more beneficial in vitamin D-deficient patients.

Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis.[Pubmed:26550211]

Int J Clin Exp Med. 2015 Aug 15;8(8):12935-41. eCollection 2015.

BACKGROUND: Published literatures report controversial results about the effect of combined treatment with alendronate and Alfacalcidol for the prevention of fractures in osteoporosis patients. METHODS: Seven common databases were searched for related randomized controlled trials published up to April, 2015. Bayesian random effects network meta-analysis was used to assess the pairwise odds ratios (OR), 95% credible intervals (CI). RESULTS: Thirteen randomized controlled trials were identified (3710 patients). The network meta-analysis results indicated that combining treatment with alendronate and Alfacalcidol was significantly better to prevent bone fractures in osteoporosis patients than alendronate (OR=0.53, 95% CI: 0.19-0.95) and Alfacalcidol (OR=0.25, 95% CI: 0.08-0.49). In addition, there was no significant difference for adverse events among the three therapeutic regimen. CONCLUSIONS: Combined treatment with alendronate and Alfacalcidol was more active than the monotherapies in preventing bone fractures in osteoporosis patients. Large-scale randomized, controlled trials are recommended to confirm the result.

Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.[Pubmed:27822674]

Int Urol Nephrol. 2017 Feb;49(2):325-328.

PURPOSE: The optimal vitamin D3 therapy for the treatment of secondary hyperparathyroidism (SHPT) in chronic hemodialysis patients is still controversial. Recent studies suggest that uremia in end-stage renal disease is associated with enzymatic hepatic dysfunction altering 25-hydroxylation of vitamin D3. The goal of our study was to compare the efficacy of calcitriol, the fully hydroxylated active form of vitamin D3, to Alfacalcidol which needs 25-hydroxylation to be effective, for the treatment of SHPT in chronic hemodialysis patients. METHODS: We retrospectively reviewed 45 chronic hemodialysis patients who were switched from oral Alfacalcidol to oral calcitriol for the treatment of SHPT. Parathyroid hormone (PTH), serum calcium and serum phosphorus levels were compared pre- and post-conversion using paired Student's t tests. RESULTS: The mean dose of active vitamin D3 decreased from 3.50 mcg/week at baseline to 2.86 mcg (P < 0001) after the switch from Alfacalcidol to calcitriol. PTH significantly decreased from 94.4 to 82.6 pmol/L (-11.8 pmol/L, P = 0.02). The mean corrected calcium increased from 2.17 to 2.25 mmol/L (+0.08 mmol/L, P < 0.001) without any clinically significant hypercalcemia, and phosphorus levels were stable. Results were similar in a subgroup of patients (n = 17) for whom the medication was administrated during the hemodialysis session, ensuring a complete compliance. CONCLUSIONS: According to our study, calcitriol in equal dosage is more effective than Alfacalcidol in lowering serum PTH level in chronic hemodialysis patients. This suggests that calcitriol may be the optimal active vitamin D3 for the treatment of SHPT in chronic hemodialysis patients.

Description

Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis.

Keywords:

Alfacalcidol,41294-56-8,1-Hydroxycholecalciferol,Natural Products,VD/VDR, buy Alfacalcidol , Alfacalcidol supplier , purchase Alfacalcidol , Alfacalcidol cost , Alfacalcidol manufacturer , order Alfacalcidol , high purity Alfacalcidol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: